In the EUROASPIRE III study [7], conducted from 2006 to 2007, 94.2% of patients with coronary heart disease were treated with antiplatelet drugs, 90.1% with lipid-lowering drugs, 81.6% with beta-blockers and 71.5% with ACE-Is or ARBs. The gene discussed is ACE; the disease is coronary artery disorder.